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AntimicrobialThe human gut microbiota comprises approximately 100 trillion microbial cells and has a signiﬁcant
effect on many aspects of human physiology including metabolism, nutrient absorption and
immune function. Disruption of this population has been implicated in many conditions and
diseases, including examples such as obesity, inﬂammatory bowel disease and colorectal cancer that
are highlighted in this review. A logical extension of these observations suggests that the manipu-
lation of the gut microbiota can be employed to prevent or treat these conditions. Thus, here we
highlight a variety of options, including the use of changes in diet (including the use of prebiotics),
antimicrobial-based intervention, probiotics and faecal microbiota transplantation, and discuss
their relative merits with respect to modulating the intestinal community in a beneﬁcial way.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Humans are now thought of as ‘‘superorganisms’’ on the basis of
the genetic potential encoded within our resident microbial popu-
lations in addition to our own genome. It has been suggested that
our microbiota develops with us and alters its own composition
and gene expression in response to changing environmental condi-
tions [1]. The largest and most varied of the human-associated
microbial communities exists in the gastrointestinal (GI) tract.
The gut microbial population is made up of approximately 1000
species from relatively few phyla. The most abundant species are
members of the phyla Firmicutes and Bacteroidetes, with smaller
numbers being representatives of the Proteobacteria, Fusobacteria,
Cyanobacteria, Verrucomicrobia and Actinobacteria, amongst
others [2]. The gut microbiota is composed mainly of anaerobes,
which outnumber facultative anaerobes and aerobic bacteria by
approximately 2–3 orders of magnitude [3]. It has been noted that,
although there is great inter-individual variation in the composi-
tion of the gut microbiota, there are a conserved set of encoded
functions shared between individuals referred to as the core gut
microbiome [4], suggesting that it is the functionality of the micro-
biota rather than its composition that is of greatest importance tothe host. The functions and pathways encoded in the core microb-
iome are thought to confer the greatest beneﬁt to the host and
are probably essential for the correct functioning of the gut.
Some well-studied beneﬁts include protection against potential
pathogens, digestion of polysaccharides, production of essential
vitamins, stimulation of angiogenesis, regulation of fat storage
and modulation of the host’s immune system [5]. Recent studies
have also shown that the gut microbiota inﬂuences the gut-brain
axis and shapes stress-related symptoms such as anxiety and pain
tolerance [6].
Advances in high throughput sequencing technologies (HTS)
and tools enabling comparative analysis of the large amount of
data that are generated by these technologies have led to a better
understanding of what constitutes a ‘healthy’’ gut microbiota. One
of the most interesting observations drawn from the data gener-
ated is that the resident microbiota encodes >100-fold more genes
than the human genome [7]. The genes present in the microbiome
are responsible for many functions essential to host survival but
which are not encoded within the human genome. Due to the
range and importance of the metabolic and biochemical processes
carried out by the microbiome it has been referred to as ‘‘our
hidden organ’’ [8].
While the ‘‘healthy’’ gut microbiota is seen to be a stable
community, there are stages within the life cycle of humans during
which there can be dramatic alterations in the structure and func-
tion of this population. These ‘‘natural’’ changes begin with initial
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ment of the microbiota over the ﬁrst 2 years of life. The earliest col-
onizers are usually members of the enterococci and enterobacteria
followed by strict anaerobes such as Biﬁdobacterium, Clostridium
and Bacteroides spp. once the initial oxygen supply present has
been depleted [9]. Despite this general pattern, it is important to
appreciate that the method of delivery and subsequent feeding
type have a profound effect on the initial populations [10]. Once
the infant reaches 2 years of age the microbiota has already begun
to transform into its adult form, which is thought to be relatively
stable before it undergoes a ﬁnal ‘‘shift’’ when entering old age
[11]. Indeed, with respect to the latter phenomenon, a study by
Claesson and colleagues that compared the gut microbiota of indi-
viduals ages 65 or older to 9 younger control subjects has high-
lighted signiﬁcant changes in community structure associated
with ageing, speciﬁcally an increase in the abundance of Bacteroi-
des spp. and distinct shifts within the Clostridium genus [12]. It
has been hypothesised that alterations in the elderly microbiota
are due to physiological changes in the elderly GI tract such as
chronic low-grade inﬂammation, in addition to dietary habits [13].
It has been well established that the human gut microbiota is
integral to human health, and, as will be discussed below, it also
plays an important role in GI disease. It is therefore reasonable to
assume that modulation of the gut microbiota can be used as a
therapeutic approach to treating chronic GI diseases. Thus, this
review is focussed primarily on the methods that can be employed
to modulate the gut microbiota while highlighting the beneﬁt of
guiding community structure towards a more desirable state.
2. Role of the gut microbiota in gastrointestinal disease
There are a growing number of GI conditions that have been
linked with alterations in the gut microbiota. To properly imple-
ment strategies to modulate the gut microbiota as a therapeutic
tool, it is ﬁrst necessary to understand the role of the gut microb-
iome in speciﬁc GI, and other, diseases. Given the recent rapid
expansion in the number of disease states that have been linked
with alterations in the gut microbiota, it is not possible to address
the issue in depth in the conﬁnes of this review. Instead, some
well-studied examples are discussed below and we refer you to
some other recent reviews that address this topic in depth [3,14].
2.1. Inﬂammatory bowel disease
Inﬂammatory bowel disease (IBD) is a relapsing disorder char-
acterised by chronic inﬂammation of the GI tract, and of the colon
in particular. The two major types of IBD are Crohn’s disease (CD)
and ulcerative colitis (UC). Evidence suggests that IBD is a complex
disease arising from a combination of genetic and environmental
factors. From a genetics perspective, genome-wide association
studies (GWAS) and subsequent meta-analyses have identiﬁed a
total of 163 genetic risk loci for IBD [15–17]. A German twin cohort
study conﬁrmed the strong genetic element to IBD by observing
that monozygotic twins are signiﬁcantly more likely to be concor-
dant for the disease than dizygotic twins [18]. However, concor-
dance rates between monozygotic twins are nonetheless low
(35% for CD and 16% for UC), highlight that environmental triggers
do indeed play an important role in both diseases, and in UC in
particular.
It is notable that murine studies have revealed that the presence
of commensal enteric bacteria is necessary for the development of
spontaneous colitis and immune system activation [19] and,
indeed, transferring colitogenic gut microbiota into healthy mice
can induce spontaneous colitis [20]. Similarly, it has consistently
been observed that patients suffering from IBD harbour an altered
gut microbiota [21,22], speciﬁcally reduced bacterial diversity andchanges within the Firmicutes phylum [23]. The changes in micro-
biota composition appear to be somewhat different between UC
and CD. For example, decreased abundance of the butyrate-
producing bacteria Roseburia hominis and Faecalibacterium
prausnitzii have been observed in UC patients relative to controls
[24], while the opposite has been observed in CD patients who
possessed increased F. prausnitzii levels in addition to a reduced
overall diversity [25]. Although these microbial changes could be
a result of increased inﬂammation, evidence suggests that it is
more likely that shifts in the microbiota are involved in the
disease’s pathogenesis, either due to an intolerance to a speciﬁc
group of commensals or due to an imbalance between protective
and harmful members of the population [21,23,26].
2.2. Irritable bowel syndrome
Irritable bowel syndrome (IBS) is a chronic GI disorder that pre-
sents with symptoms including abdominal pain, bloating and
altered bowel function. IBS is divided into several subtypes based
on stool characteristics; diarrhoea, constipated or mixed. It’s cause,
as of yet, is not fully known and although the aetiology is thought
to be a combination of a number of factors, it is hypothesised that
perturbations in the normal microbial microbiota play a role in the
syndrome’s characteristic low-grade inﬂammation [27]. Indeed,
Rajiic´-Stojanovic´ et al. used qPCR and phylogenetic microarrays
to show that the gut microbiota of IBS patients differed signiﬁ-
cantly from healthy controls, with IBS sufferers having a 2-fold
higher Firmicutes to Bacteroidetes ratio and correlation analysis
implicating several groups of Firmicutes and Proteobacteria in
IBS pathogenesis [28]. Contrastingly, Jalanka-Tuovinen and col-
leagues observed that the faeces of diarrhoea-predominant IBS suf-
ferers harboured 12-fold higher levels of several Bacteroidetes
members. This group also noted that healthy controls have 35-fold
higher numbers of uncultured clostridia [29]. Interestingly, these
alterations in the microbiota correlated with changed in expression
of host genes involved in amino acid synthesis, cell junction integ-
rity and inﬂammatory response, suggesting impaired epithelial
barrier function in IBS patients. Small intestinal bacterial over-
growth (SIBO), which is characterised by excessive bacteria in
the small intestine, has also been put forward as a possible factor
in IBS aetiology [30]. Bacterial overgrowth can result in overpro-
duction of gas in the small intestine by degradation of carbohy-
drates, contributing to the symptoms of IBS [31]. The most
commonly isolated bacteria from SIBO patients are Escherichia coli,
Streptococcus, Lactobacillus, Bacteroides and Enterococcus species
[32]. However it is not fully understood if any of these microorgan-
isms play a speciﬁc role in IBS progression. It should also be recog-
nised that differences between studies may be due to the causative
microorganisms or imbalances differing between IBS subtypes.
Regardless, a bacterial role in IBS onset would seem to be clear,
as further evidenced by the disease’s response to antibiotic therapy
[33] and differential expression levels of Toll-like receptors in colo-
nic biopsies of patients with IBS [34].
2.3. Obesity
Obesity is a complex disease resulting from a prolonged imbal-
ance of energy input and energy expenditure. Modern dietary and
exercise habits are major contributing factors but it is now under-
stood that the composition and function of the gut microbiome
plays an important role through a variety of mechanisms [35]. A
number of comprehensive reviews focussing on the association
between the microbiota and obesity have been published [36,37].
Differences in the gut microbiota between obese and lean individ-
uals have been the subject of great scrutiny. A range of different
murine models have been used to this end, including genetically
4122 C.J. Walsh et al. / FEBS Letters 588 (2014) 4120–4130obese [38,39], diet-induced obese [40] and humanized [41] mice.
Although a number of studies have reported an increased ratio of
Firmicutes to Bacteroidetes in obese mice compared to their lean
counterparts, these ﬁndings continue to be the subject of much
debate in relation to human studies, which have revealed a number
of microbial populations that have been associated with obesity
[37]. Notably, transplanting the faecal microbiota of obese humans
into germ-free mice brought about signiﬁcant increases in the fat-
mass of, and obesity-related metabolic phenotypes in, these mice
relative to those which occurred when the corresponding faecal
microbiota from lean monozygotic twins was transplanted [42].
Furthermore, a second trial showed that cohousing mice harbour-
ing these two microbial communities prevented development of
the obese phenotype, a trend correlating with invasion of speciﬁc
Bacteroidetes members from lean to obese microbiota [42].
Another recent paper of note has linked the mucin-degrading bac-
terium Akkermansia muciniphila with obesity and type 2 diabetes
(T2D) [43]. The study showed A. muciniphila abundance was
decreased in obese and type 2 diabetic mice and that prebiotic
feeding normalised A. muciniphila levels, which in turn correlated
with an improvedmetabolic proﬁle. Orally administered A. muciniphil-
a also reversed high-fat diet induced metabolic disorders in these
mice [43]. The results of these, and other studies, make it apparent
that the microbiota plays a role in obesity but the speciﬁc changes
associated with the phenotype are complex and remain unclear.
2.4. Type 2 diabetes
T2D is a metabolic disorder with both genetic and environmen-
tal inﬂuences. It is a major health concern throughout the western
world, arising particularly as a result of increasing obesity-related
insulin resistance [44,45]. It is evident from a number of studies
that the gut microbiome is altered in patients suffering from T2D
[46–48], although, as with many obesity-related associations, it
is not clear whether these changes are a cause or simply a conse-
quence of the disorder. Nonetheless, it was an interesting develop-
ment when, in 2010 it was reported that the proportions of
Firmicutes, and in particular species of clostridia, were signiﬁ-
cantly reduced in T2D sufferers compared to healthy individuals
[46]. A subsequent, and much larger, metagenome-wide associa-
tion study of 345 Chinese individuals showed that the gut microbi-
ota of patients with T2D was characterised by a moderate degree of
microbial dysbiosis, lower levels of butyrate-producing bacteria
and an enrichment of microbial functions relating to sulfate reduc-
tion and resistance to oxidative stress [48]. Almost all of the micro-
bial genes enriched in T2D patients were from opportunistic
pathogens, including genes from several Clostridium spp. as well
as Bacteroides caccae [48]. These results provided a number of
markers that were assessed to determine if they could successfully
identify patients with T2D on the basis of an analysis of faecal sam-
ples. Notably, this method successfully identiﬁed the T2D disease
state with 81% accuracy [48], i.e. a greater success rate than using
a combination of clinical risk factors and genetic information [49].
2.5. Colorectal cancer
Colorectal cancer (CRC) is the third most common cause of can-
cer mortality in the world [50]. It is becoming apparent that, even
though a single causative microorganism has not been explicitly
identiﬁed, the gut microbiota plays a role in CRC [51,52]. Wang
and colleagues noted that there was a clear segregation between
the microbiota of CRC patients and healthy volunteers, particularly,
as was the case for T2D, a decrease in the abundance of butyrate
producers and an increase in the incidence of opportunistic patho-
gens in CRC patients [53]. Members of the Fusobacterium genus
have also been recently identiﬁed as potential causative agentsafter it was observed that they were enriched in colorectal carcino-
mas [54], a pattern also noted in other studies [53,55–57]. The
authors hypothesised that Fusobacterium spp. may contribute to
tumourigenesis by an inﬂammatory-mediated mechanism, a
hypothesis supported by a follow-up study which showed that
members of fusobacteria could generate a proinﬂammatory micro-
environment through the recruitment of tumour-inﬁltrating im-
mune cells [58]. E. coli has also been linked with CRC in a number
of studies. Arthur et al. observed that E. coli levels were 100-fold
higher in the microbiota of the colitis-susceptible IL10/ mouse
strain compared to the wild type [51]. They went onto show that
E. coli NC101 mono-association signiﬁcantly promoted develop-
ment of invasive mucinous adenocarcinomas in azoxymethane
treated, IL10/ mice and that deletion of the polyketide synthase
(pks) genotoxic island from this E. coli strain decreased tumour
multiplicity and invasion [51]. While further investigations are
required, these results suggest that colitis promotes tumourigene-
sis in mice by altering the composition of the gut microbiota and
selecting for members with genotoxic capabilities.
Ultimately, identiﬁcation of microorganisms, microbial popula-
tions or microbial functionalities involved in GI disease is funda-
mental to developing novel therapies. It is evident that the gut
microbiota plays a large role in intestinal health and disease, and
therefore manipulation or modulation of this community, is a clin-
ical option that merits serious consideration.
3. Modulation of the gut microbiota
3.1. Modulation by diet
Environmental factors, including dietary intake, can shape the
composition of the intestinal microbial community Fig. 1. Indeed,
a number of recent studies have highlighted the links between diet
and distinct microbial proﬁles and, in turn, overall gut health
[40,59–63]. Having an understanding of how diet inﬂuences micro-
bial communities will be of critical importance with respect to
employing food to beneﬁcially alter the gut microbiota.
The amount, type and balance of the three main dietary compo-
nents, i.e. protein, carbohydrates and fat, have a profound impact
on the gut microbiota. Short-chain fatty acids (SCFAs), primarily
butyrate, propionate and acetate, are the major end products from
the microbial degradation of carbohydrates and protein in the gut.
SCFAs have a diverse range of physiological effects on the host,
with perhaps the most important being their oxidation by mucosal
cells to provide energy. An excellent review of the beneﬁts of SCFAs
on the host has been published by Macfarlane & Macfarlane [64].
The majority of microbial protein degradation occurs in the distal
colon where the pH is neutral and conditions are favourable for
the growth of proteolytic bacteria such as Bacteroides spp., Propion-
ibacterium spp. and Clostridium perfringens [65,66]. The main path-
way of protein degradation by this population is deamination of
amino acids to the aforementioned SCFAs and ammonia [67], high
concentrations of the latter have been shown to act as tumour pro-
moters in rats [68]. The range of end products generated by protein
digestion is broader than that of carbohydrates (see below) and
also includes branched-chain amino acids, phenols, indoles and
amines [69]. The majority of studies examining the effect of dietary
protein on the gut microbiota have focussed primarily on the
detection of altered fermentation products in the cecum [70] and
faeces [71]. However, the effects of whey protein isolate on the
microbiota have been the topic of some scrutiny in recent years
as it has been indicated that dairy products can alleviate several
disorders relating to metabolic syndrome [72]. One such study
noted signiﬁcantly increased counts of biﬁdobacteria and lactoba-
cilli in the faeces of rats whose diets included cheese whey protein
isolate or casein supplemented with either threonine or cysteine
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the composition of the gut microbiota of mice in a dose-dependent
manner [74]. All mice whose high fat diet was supplemented with
WPI had signiﬁcantly increased proportions of Lactobacillaceae and
signiﬁcantly decreased proportions of Clostridiaceae compared to
high-fat fed controls, and increasing the amount of total energy de-
rived from WPI caused a more profound shift in the microbiota
[74]. Certain components of the normal human dietary intake of
carbohydrates cannot by digested directly by the host and act as
the major diet-derived energy source for microorganisms in the
gut [75]. This fraction, comprised largely of resistant starches and
non-starch polysaccharides, is degraded by microbial fermentation
to a mixture of gasses and the aforementioned SCFAs. Many such
carbohydrates are also referred to as prebiotics. The term prebiotic
was introduced by Gibson and Roberfroid in 1995 [76] and are de-
ﬁned as ‘‘selectively fermented ingredients that allow speciﬁc
changes, both in the composition and/or activity in the GI micro-
ﬂora that confer beneﬁts upon host well-being and health’’ [77].
Prebiotics have most frequently been employed with a view to
stimulating the growth of either lactobacilli or biﬁdobacteria, with
many studies focussing on inulin [78–80], oligofructose [81,82] or
fructooligosaccharides [83,84]. There is a substantial body of evi-
dence linking prebiotic consumption to human health beneﬁts
through modulation of the gut microbiota, with research in this
area having been the subject of a number of recent reviews [85–
87]. In one particularly notable recent study, it was observed that
supplementing the murine diet with SCFAs or fructooligosaccha-
rides caused a shift in microbiota composition which strongly cor-
related with beneﬁcial changes in body weight, adiposity and
glucose control. These physiological changes were brought about
via butyrate- and propionate-mediated activation of intestinal glu-
coneogenesis [88].
The majority of dietary fat is absorbed in the human small
intestine but it has been shown that a substantial amount survives
digestion and can be recovered in faeces [89]. The undigested por-
tion passes through the colon where it can have a profound effect
on the intestinal microbiota. Murphy et al. observed that high-fat
feeding caused a greater compositional change in the gut microbi-
ota than genetically induced obesity [90], in accordance with a pre-
vious study which showed that, when fed a high-fat diet, RELMb
knockout mice showed a signiﬁcantly altered gut community
while staying lean. RELMb knockout mice were employed as they
are known to stay relatively lean when fed a high-fat diet. The
authors could therefore conclude that the change in diet, as op-
posed to the obese state, was responsible for the observed changes
in the microbiota [91]. Many studies have established that mice fed
a high-fat diet have signiﬁcantly dissimilar microbial populations
in the gut compared to mice fed on normal chow [38,40,92]. How-
ever, a recently published study showed that life-long calorie
restriction signiﬁcantly altered the gut microbiota in mice fed on
both high-fat and low-fat diets [93]. This implies that not only
the fat content of the diet, but also the number of calories con-
sumed, has the potential to inﬂuence the bacterial communities
present in the GI tract. The study also linked changes in the gut
microbiota to claims that calorie restriction promotes healthy-age-
ing and increases lifespan in various animal models as the health-
iest and longest living mice were those that were fed a low fat diet
with calorie restriction [93]. In addition to the studies referenced
above, there are many excellent reviews of the effect of dietary
fat on the intestinal microbiota [37,94,95].
This speciﬁc combination of dietary components can vary
according to geographic location, food availability, cultural prac-
tices and age and can have a profound impact on the conditions
within the gut and the requirements of the microbiota (Table 1
highlights some studies which have investigated this impact). In
one instance, the faecal microbiota of European children andchildren from an African village in Burkina Faso, whose diets dif-
fered considerably, was investigated. The diet of the African chil-
dren was predominately vegetarian; high in starch, ﬁbre and
plant polysaccharides and low in fat and animal protein. This diet
correlated with a signiﬁcant increase in the Bacteroidetes:Firmi-
cutes ratio in addition to an abundance of Prevotella and Xylanib-
acter when compared to the microbiota of the children
consuming a carbohydrate-rich European diet [96]. The Xylanibact-
er genus, which was absent in European children, is known to
contain genes for xylan and cellulose hydrolysis and so it was
hypothesised that the gut microbiota coevolved with the polysac-
charide-rich diet of the Burkina Faso children, allowing them to in-
crease the energy extracted from dietary ﬁbre while also
conferring protection from inﬂammation and non-infectious colo-
nic disease [96]. The comparatively high abundance of Prevotella
in the faecal microbiota of the African children and the fact that
it coincides with a carbohydrate-rich diet is consistent with the
observations of Wu et al. who found that the overall composition
of the microbiota was strongly associated with long-term diet
[62]. Speciﬁcally, a diet rich in protein and animal fat was associ-
ated with higher proportions of Bacteroides while Prevotella were
more abundant when the diet was enriched with plant-derived
carbohydrates [62]. A recent study by De Filippo et al. took these
investigations a step further by focussing speciﬁcally on the effect
of diets composed entirely of animal or plants products on the gut
microbiota [61]. It revealed that an animal-based diet increased
the numbers of bile-tolerant microorganisms present and de-
creased the numbers of plant polysaccharide degrading Firmicutes.
Interestingly, the respective diets brought about a transcriptional
response among the gut microbiota that was consistent with pre-
viously reported differences in gene abundances between herbivo-
rous and carnivorous animals [61]. In other studies, members of
the Clostridium clusters IV and XIVa have been found to be enriched
in the faeces of omnivores compared to vegetarians and lacto-
vegetarians, who generally consume higher proportions of carbo-
hydrates as part of their diet [97–99]. These clusters of bacteria
are noted for their ability to convert dietary ﬁbre to SCFAs.
The overall dietary patterns in the De Filippo study above are
similar to a study in mice where conventionalised mice were
switched from a low-fat diet rich in complex plant polysaccharides
(CHO) to an obesity-inducing high-fat/simple carbohydrate ‘‘Wes-
tern’’ diet [40]. Mice fed on the ‘‘Western’’ diet had a signiﬁcantly
lower level of bacterial diversity, a characteristic seen to be an indi-
cator of an unhealthy microbiota [59]. These mice possessed a sig-
niﬁcantly higher relative proportion of Firmicutes and lower
relative proportions of Bacteroidetes compared to littermates
which remained on the CHO diet. This population shift is similar
to what is seen in the ob/obmouse model of obesity [38] but differs
in that the Firmicutes shift in the genetically-induced obesity mod-
el is division-wide whereas the dietary intervention above caused a
bloom in a single uncultured clade within the Mollicutes class. A
subsequent microbiota transplantation from these diet-induced
obese mice into germ-free recipients promoted greater adiposity
than transplants from lean donor [38]. A further study by the same
group showed that this response of the microbiome to dietary
intervention is rapid and can occur within 24 h [41], a phenome-
non also observed by Wu et al. [62].
A gut microbiota with decreased diversity has been linked with
increased frailty and poorer general health in elderly subjects [60].
In this study, clustering of subjects by diet, residence location and
by microbial groupings was apparent. Ultimately, it was evident
that subjects that were living in the community had a healthier
and more varied diet than subjects in long-term residential care,
which gave rise to a more diverse gut microbiota with signiﬁcant
changes being noted at phylum and family levels. Differences were
also apparent at the genus level with long-stay subjects possessing
Table 1
Some examples of studies assessing the inﬂuence of diet on the microbiota and health of the host.
Diet Effect on microbiota Effect on host
Rich in plant-derived
polysaccharides [96,62]
Increased Bacteroidetes, decreased Firmicutes [96].
Associated with Prevotella-rich enterotype [62]
Faster gut transit time compared to high protein and
animal fat diet [62]
Omnivorous compared to
vegetarian and lacto-
vegetarian [97–99]
Increased Clostridium clusters IV and XIVa [97–99] Not reported
High-fat, simple carbohydrate
‘‘Western’’ diet [38,40]
Increased Firmicutes, decreased Bacteroidetes [38,40] Diet-induced obesity. Subsequent transplantation of
obese microbiota to germ free mice increased adiposity
[40]
Reduced carbohydrate intake
[63]
Reduced Biﬁdobacterium, Roseburia spp. and Eubacterium rectale [63] Not reported
Animal product-based [61]. High
protein and animal fat [62]
Increased b-diversity and bile-tolerant bacteria, including Bacteroides,
decreased Firmicutes [61]. Associated with Bacteroides-rich enterotype
[62]
Decreased weight independent of calories consumed
[61]
Less fruit, vegetables and ﬁsh
[100]
Reduced microbial gene richness [100] Increased insulin resistance, fasting serum triglyceride
levels, LDL cholesterol and inﬂammation [100]
Reduced variety due to long-stay
care [60]
Increased Bacteroidetes and reduced overall diversity [60] Increased frailty and poorer general health [60]
Changed from a vegetarian diet
to an animal-based diet [61]
Decreased Prevotella, increased Bacteroides [61] Not reported
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ifactor and Coprobacillus, while Coprococcus and Roseburia (both
members of the Lachnospiraceae family) were more abundant in
community-dwelling subjects [60]. The data also linked microbiota
composition to the duration spent in long-stay care. The longer the
subject stayed in residential care (and consumed a less varied diet),
the more dissimilar their microbiota became to the microbiota of
healthy community-dwelling subjects [60]. Another study investi-
gating the temporal relationship between food intake, gut microbi-
ota and metabolic and inﬂammatory phenotypes reported that
individuals with reduced microbial gene richness present more
pronounced dys-metabolism and low-grade inﬂammation than
their richer counterparts [100]. This microbiota-associated pheno-
type was suggested to be a result of long-term dietary habits as it
was noted that these subjects seemed to consume less fruits, veg-
etables and ﬁsh than their high gene richness equivalents, i.e. a
pattern consistent with that reported by Claesson et al. [60]. More
speciﬁcally, the initial sampling of the cohort (49 obese or over-
weight subjects) showed that subjects with lower gene richness
in the gut microbiota presented with increased obesity-associated
phenotypes such as higher insulin resistance and increased levels
of fasting serum triglyceride, LDL cholesterol and inﬂammation.
Dietary intervention (6 week energy-restricted high-protein diet)
increased gene richness signiﬁcantly in individuals that originally
had a low gene count. This increased gene richness remained after
the subjects were switched to a 6 week weight-maintenance diet
suggesting that dietary intervention as the potential to, at least
partially, correct a loss of richness in the microbiota [100].
Given the complexity of the relationship between diet and the
gut microbiota, there would seem to be merit in developing and
utilising models that allow one to elucidate the speciﬁc relation-
ship between speciﬁc dietary components and microorganisms.
An elegant strategy to facilitate this was provided by Faith et al.
when they introduced a model community of ten human gut bac-
teria into gnotobiotic mice and developed a relatively simple sta-
tistical model which predicted over 60% of the species variations
that occurred in response to changes in diet [101]. The amount
of casein in the diet was observed to be signiﬁcantly associated
with the abundances of all 10 microbial species and highly corre-
lated with the total biomass of the community. Interestingly,
E. coli and Clostridium symbosium were the only two species that
had a second dietary variable signiﬁcantly associated with their
abundance, sucrose and starch respectively. The statistical model
was subsequently able to determine 61% of the variation of thecommunity members when the host was fed a new, previously un-
seen diet [101]. These results represent a signiﬁcant step towards
tailoring diet to address chronic microbiota-associated illnesses
and a potential evolution of research within the ﬁeld.
It is clear that microbial composition varies between groups liv-
ing on different long-term diets. Recent investigations that suggest
that short-term dietary changes can also alter the composition, and
result in changes to the metabolic activity of the microbiome as a
whole, are noteworthy but further investigations are required to
determine how best to take advantage of these observations.
3.2. Modulation by antimicrobials
The manipulation of the gut microbiota by antimicrobials is
emerging as an attractive therapeutic strategy (Table 2). The suc-
cess of this approach is likely to ultimately depend on the target
speciﬁcity of the antimicrobials in question, especially as the unde-
sirable consequences of the overuse of broad-spectrum antimicro-
bials have become ever more apparent in recent years. For quite
some time broad-spectrum antibiotics have been commonly used
by clinicians as they can be used in the treatment of a wide range
of infections or when the causative bacterium has not been for-
mally identiﬁed. However, due to the frequent use of these antibi-
otics, the spread of antibiotic resistance is now posing a serious
problem in health care settings. In addition, antibiotic therapies
not only affect the target microorganism but can also perturb the
host gut microbial communities. The extent of this damage has
recently become more evident through the application of high
throughput DNA-based sequencing technologies to assess the com-
position of gut microbial populations (for review see Cotter et al.
2012) [102]. Here we provide just a few examples of the negative
consequences of the use of broad-spectrum antibiotics on the gut
microbiota and, in turn, health.
The widespread use of broad-spectrum antibiotics, such as
amoxicillin, to treat childhood infections has been linked to a
dramatic decrease in Helicobacter pylori carriage [103]. However,
studies indicate that those who did not acquire H. pylori in child-
hood were more likely to subsequently develop asthma, hay fever
and skin allergies [104], while other investigations suggest that H.
pylori infection has a protective effect with respect to the develop-
ment of allergic asthma in mouse models [105]. The use of some
broad-spectrum antibiotics, including clindamycin, ampicillin,
amoxicillin, cephalosporins and ﬂouroquinolones, can also result
in Clostridium difﬁcile overgrowth by impacting the resident gut
Faecal Microbiota 
Transplant 
Diet 
Antimicrobials 
Gut microbiota 
Probiotics 
Fig. 1. Potential strategies for manipulation of the gut microbiota.
Table 2
Some examples of studies assessing the inﬂuence of antimicrobials on the gut microbiota and, where relevant, the host.
Antimicrobial Effect on microbiota Physiological effect on host
Thuricin CD Eliminated C. difﬁcile without impacting overall
microbiota composition [113]
Not examined – distal colon model
Abp118 Protection against Listeria monocytogenes
infection [117].
Increased Bacteroidetes and Proteobacteria,
decreased Actinobacteria [120]
Temporarily reduced weight gain in pigs [117]
Vancomycin Decreased Firmicutes and Bacteroidetes,
increased Proteobacteria [121]
Decrease in weight gain, fasting blood glucose, plasma TNFa and
triglyceride levels in DIO mice [121]
Sub-therapeutic antibiotic therapy* Increased Firmicutes, especially Lachnospiraceae,
relative to Bacteroidetes [108]
Increased adiposity and bone mineral density in mice [108]
5 strain probiotic mixture** Reduced shedding of Samonella enterica serovar
Typhimurium in pigs [119]
Reduced incidence, severity and duration of diarrhoea in pigs. Also,
increased weight gain [119]
Lactobacillus gasseri SBT2055, producer
of gassericin T bacteriocin
Not reported Decreased abdominal adiposity, body weight, BMI, waist circumference
and hip circumference in human adults [131].
Lower triglyceride levels and reduced expression of lipogenic and pro-
inﬂammatory genes in DIO mice [135]
* Penicillin, vancomycin, penicillin plus vancomycin, and chlortetracycline.
** Lactobacillus murinus DPC6002, Lactobacillus murinus DPC6003, Lactobacillus pentosus DPC6004, Lactobacillus salivarius DPC6005, and Pediococcus pentosaceus DPC6006.
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membranous colitis and, potentially, life-threatening complica-
tions such as toxic megacolon [106,107]. Low doses of antibiotics
have also been used as growth promoters in agriculture since the
1950’s despite an unclear understanding of the mechanisms at
work. A recent investigation into this effect revealed subtherapeu-
tic antibiotic treatment (STAT) of various antibiotics increased
adiposity and hormones related to metabolism in young mice com-
pared to untreated controls [108]. Analysis of the composition and
function of the gut microbiota of these animals made it apparent
that STAT exposure selected for microbial species that were able
to extract more calories from dietary complex carbohydrates that
were otherwise indigestible in the control group [108].When considering these results, it is important to be aware that
different broad-spectrum antibiotics differ with respect to their
impact on the gut microbiota. Changes to the gut microbiota can
also be either long- or short-term. In one instance this was high-
lighted through murine studies which established that mice trea-
ted with a cocktail of amoxicillin, metronidazole and bismuth
[3.0, 0.69 and 0.185 mg, respectively] daily for 10 days had largely
recovered their baseline microbial community structure 2 weeks
post-treatment but that treatment with cefoperazone [0.5 mg/ml
of drinking water] had long-term effects on community structure
and reduced overall diversity [109]. The effect of an antibiotic on
the gut microbiota is inﬂuenced by several factors including its
antimicrobial effect (bactericidal or bacteriostatic), its mode of
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biotic resistance genes among this population [110].
In light of this greater appreciation of the impact of broad spec-
trum antimicrobials on the gut microbiota, it is apparent that there
is value in utilising antimicrobials with a narrow spectrum of inhi-
bition. In addition to existing repositories of narrow spectrum anti-
microbials that were not previously commercialised, it is worth
noting that the gut microbiota is considered a rich, but yet rela-
tively, underutilised source of antimicrobial-producing, and in par-
ticular bacteriocin-producing, bacteria. Bacteriocins are
ribosomally synthesised peptides to which the producer has a spe-
ciﬁc immunity gene and can have either a narrow or broad spec-
trum of activity [111]. Many bacteriocins have a number of
desirable traits, including low toxicity, high potency and, in the
case of gut associated strains, the possibility of in situ antimicro-
bial. This combination of traits makes them attractive alternatives
to traditional antibiotic therapies. Despite being, as stated above, a
relatively underutilised source of antimicrobials, a number of bac-
teriocins have previously been isolated from mammalian gut
microbes [112–115]. Indeed, for example, screening of faecal
samples from 266 elderly Irish subjects identiﬁed 13 bacteriocin
producing strains [115] while a further study lead to the isolation
of 23 distinct bacteriocin-producing strains from a range of mam-
malian gastrointestinal sources [112]. Given that, for a bacteriocin
to be produced and be active in the gut, the producer needs to be
able to survive in and colonize the human gut and the associated
antimicrobial needs to be active in the gut environment, it has
been argued that the gut is an ideal source of bacteriocin producers
with the potential to alter the gut microbiota [116]. There have
already been a number of studies which have highlighted the merits
of employing gut-associated bacteriocins, several of which we refer
to here. In a distal colon model, the narrow spectrum bacteriocin
thuricin CD has been observed to inhibit the growth of C. difﬁcile
without having any signiﬁcant additional impact on the other com-
ponents of the gut microbiota [113]. This contrasted with the sig-
niﬁcant shift in the relative proportions of the dominant bacterial
populations that were observed when the broad-spectrum antimi-
crobials lacticin 3147, metronidazole and vancomycin, respec-
tively, were employed. Notably, thuricin CD also exhibited a
potency comparable to that of the control antimicrobials [113],
thereby establishing that thuricin CD has potential as an alterna-
tive to the conventional antimicrobial strategies employed to treat
C. difﬁcile infection, especially as it is less likely to impact nega-
tively on the commensal gut microbiota and, thus, is more likely
to prevent recurrent C. difﬁcile infections. While, in the above
example, thuricin CD, rather than the associated Bacillus thuringi-
ensis producer [106], was employed, there are other examples that
have highlighted the merits of using the bacteriocin-producing
strain itself. In one such instance, ingestion of the bacteriocin pro-
ducing probiotic strain Lactobacillus salivarius UCC118 provided
signiﬁcant protection against infection by Listeria monocytogenes
in mice [117]. Production of the Abp118 bacteriocin by UCC118,
which has previously been shown to be capable of altering the
intestinal microbiota of pigs and mice [118], proved to be the
key protective factor as a non-bacteriocin producing mutant failed
to confer the same protection. This protective effect was also lost
when infection was with a bacteriocin-immune L. monocytogenes
mutant, thereby conﬁrming that the mode of action was direct
antagonism by Abp118 rather than via some other indirect effect
[117]. In another instance a combination of 5 probiotic strains
were employed to control Salmonella typhimurium-induced diar-
rhoea in pigs [119]. It was subsequently established that the only
bacteriocin-producing strain, L. salivarius DPC6005, was the domi-
nant member of the cocktail in both the ileum digesta and in the
mucosa. It could not be established, however, if bacteriocin pro-
duction was directly responsible for anti-Salmonella activity [120].In addition to the control of pathogens, antimicrobials have also
been investigated with a view to altering metabolic health in diet-
induced obese mice [121]. Supplementation of a high-fat diet with
vancomycin caused a signiﬁcant decrease in Firmicutes and Bacter-
oidetes populations with a corresponding increase in Proteobacte-
ria. This compositional shift was accompanied by a marked
decrease in weight gain, fasting blood glucose, plasma TNFa and
triglyceride levels compared to the diet-induced obese controls.
Although supplementation of the high-fat diet with the bacterio-
cin-producing probiotic L. salivarius UCC118 did not produce any
signiﬁcant changes in the metabolic proﬁles of the mice, it did
result in an increase in relative proportions of Bacteroidetes and
Proteobacteria with a corresponding decrease in Actinobacteria.
The authors concluded that antimicrobial strategies have the
potential to alter both the composition of the gut microbiota and
the metabolic health of the host. However, it was noted that care
must be taken when choosing the antimicrobial to be used so as
to bring about extended beneﬁcial impacts on metabolic health.
As with diet, the vast majority of work concerning modulation
of the microbiota by antimicrobials has taken place in mouse mod-
els. Nevertheless, the results are encouraging and suggest that
carefully selected antimicrobials represent a viable option with
respect to intelligently altering the bacterial populations within
the human gut.
3.3. Modulation by probiotics
The World Health Organization deﬁnes probiotics as ‘‘live
microorganisms which when administered in adequate amounts
confer a health beneﬁt on the host’’ [122]. Probiotics are becoming
increasingly popular and are generally marketed as functional
foods or dietary supplements. As it has been recognised that
changes in the gut microbiota play a role in GI disease then it is
not surprising that probiotics are an attractive option with respect
to modulation of the gut microbiome. For a probiotic to success-
fully exert its beneﬁt on the host’s gut microbiota it should be able
to remain viable during storage and also be capable of surviving,
and potentially colonizing, the host’s intestinal environment
[123]. The majority of probiotics currently used are members of
lactic acid bacteria (LAB) and, more speciﬁcally, strains from the
genera Lactobacillus and Biﬁdobacterium are most commonly used
in commercial probiotics. Mixtures of these strains are becoming
increasingly popular as researchers gain a deeper understanding
of increasing efﬁcacy via possible additive or synergistic effects
[124]. Rijkers et al. categorised the beneﬁt of probiotics into three
levels based on location and method; (1) interference with the
growth or survival of pathogenic microorganisms in the gut lumen,
(2) improvement of mucosal barrier function or mucosal immune
system and (3) inﬂuence beyond the gut through the systemic im-
mune system and other organs [125]. A study undertaken by Park
et al. found that DIO mice treated with the probiotic strains Lacto-
bacillus curvatus HY7601 and Lactobacillus plantarum KY1032 expe-
rienced reduced body weight gain and fat accumulation in addition
to lowered plasma insulin, leptin, total-cholesterol and liver toxic-
ity biomarkers compared to a group on the same diet supple-
mented with a placebo [126]. Supplementation with these
probiotic strains also resulted in down-regulation of pro-inﬂam-
matory genes in adipose tissue, up-regulation of fatty acid oxida-
tion-related genes in the liver and signiﬁcant alterations in the
diversity and function of the gut microbiota. Similar results were
observed by Yadav et al., who found that administration of the
probiotic VSL#3 prevented and treated obesity and diabetes in a
number of different murine models through modulation of the
gut microbiota. In particular, an increase in the number of buty-
rate-producing bacteria was linked with enhanced secretion of
the hunger-reducing hormone GLP-1 as well as upregulation of
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et al. observed that, in gnotobiotic mice harbouring a 15-member
model human gut microbial community, introduction of 5 probi-
otic strains isolated from a fermented milk product did not signif-
icantly alter the composition of the intestinal microbiota but
instead increased the expression of microbial genes involved in
carbohydrate and nucleotide metabolism while decreasing expres-
sion of genes involved in the metabolism of lipids and amino acids
[128]. These metatranscriptomic changes were also apparent in the
microbiota of human monozygotic twins when fed the same fer-
mented milk product, primarily upregulation of genes involved in
carbohydrate metabolism. In addition to their investigation with
a view to contributing to the prevention/treatment of obesity
and T2D, it should be noted that probiotics are thought to have
the potential to treat a wide range of other conditions such as
IBS, allergies, C. difﬁcile infection, IBD and others by modulation
of the gut microbiota as highlighted in a number of recent manu-
scripts [129–135]. As we learn more about other gut microbes
and their role in human health it may emerge that the future of
probiotics lies in different, non-traditional probiotics, for example
Akkermansia muciniphila as mentioned previously [43]. A recent re-
view by Neef and Sanz discusses some of the strains already being
investigated and the new techniques employed to assess their im-
pact on human health [136].
3.4. Modulation by faecal microbiota transplantation
Following on from the probiotics principle, but on a community
rather than strain level, faecal microbial transplantation (FMT) is
the process of transplanting faecal bacterial communities from a
healthy individual to a recipient whose microbiota has been
disrupted or altered. Although still somewhat in its infancy, FMT
is becoming more commonly used as an approach to replenish
the gut microbiota in order to alleviate the symptoms of disease.
To date, FMT has most commonly been used to treat recurrent C.
difﬁcile infection (CDI) by replacing populations of commensal bac-
teria which have been wiped out by antibiotic therapy. Khoruts
and colleagues used terminal-restriction fragment length polymor-
phism and 16S rRNA approaches to compare the bacterial compo-
nent of a CDI patient’s microbiota before and after FMT
intervention [137] and found that, before intervention, the micro-
biota was deﬁcient in both Bacteroidetes and Firmicutes but
14 days post-transplantation the microbiota was changed to
closely resemble the donor’s microbiota and was dominated by
Bacteroides spp. [137]. These results are similar to ﬁndings by
Tvede and Rask-Madsen who reported Bacteroides spp. were absent
in CDI patients but were replenished after FMT intervention [138].
The composition of the donor’s microbiota is the key factor in
determining the efﬁcacy of this treatment, as shown by Grehan
et al. who collected faecal samples from patients undergoing FMT
at 4 time points; pre-treatment and at intervals of 4, 8 and
24 weeks post-treatment to determine the effect of FMT on its
microbial content [138]. Using a molecular approach they found
that the microbiota was altered by FMT intervention and that at
4, 8 and 24 weeks the community of the recipient was composed
predominately of bacteria derived from the healthy donor’s sam-
ples. Crucially, in addition to bringing about desirable microbi-
ota-related changes, FMT has in a high frequency of cases been
successful in controlling CDI. In one such study it was revealed that
only 1 of 16 patients treated with FMT experienced a recurrence of
colitis during the 90 day follow-up period [139]. Indeed, when
many such studies were combined in a systematic literature re-
view by Gough et al., i.e. to examine the effect of FMT on 317
CDI patients across 27 case studies, it was revealed that disease
was resolved in 92% of cases [140]. An interesting development
in the application of FMT is the use of synthetic microbialcommunities in place of undeﬁned mixtures from donors (for
review see de Vos et al. [141]). The synthetic mixtures have the
advantage of being controlled, tested extensively for the presence
of viruses or pathogens and have the potential to be reproducibly
manufactured. Petrof et al. showed that a deﬁned mixture of 33
isolates, when administered during a colonoscopy, cured the CDI
of 2 patients who had previously failed to respond to antibiotic
treatment [142]. 16S rRNA analysis showed that the strains found
in the stool substitute were rare in the patient’s gut microbiota
before intervention, however following treatment these strains
accounted for over 25% of sequences recovered from the gut mic-
robiota. Although FMT has been most extensively studied with a
view to CDI treatment, it has, however, also been investigated as
a potential treatment option for a range of microbiota-associated
diseases including IBD, IBS, obesity, idiopathic thrombocytopaenic
purpura and even multiple sclerosis. A recently published review
by Borody et al. summarises the current state of research and
possible future directions of the technique [143].4. Concluding remarks
It is well established that the gut microbiota inﬂuences host
metabolism, nutrient absorption and immune function, and that
disruption of this balanced community can have very serious
health implications. As we gain a deeper understanding of the
speciﬁc relationships between the gut microbiota and disease, we
expose potential therapeutic targets. Intelligent modulation of
the intestinal community is a topic that had gained considerable
interest and has the possibility to be extremely beneﬁcial for
human health.
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